Minoxytop
Minoxytop Price range: $ 43,00 through $ 377,00
Back to products
Mircette
Mircette Price range: $ 75,00 through $ 174,00

Mintop Solution

Price range: $ 9,00 through $ 213,00

Mintop Solution is a powerful topical treatment specifically designed to combat hair thinning and promote regrowth for those experiencing hereditary hair loss. The formula works by revitalizing hair follicles and stimulating blood circulation in the scalp to encourage the development of thicker, healthier strands. Regular application helps to stabilize hair loss and increase overall hair density over time. This fast-absorbing solution is easy to incorporate into any daily routine, providing a convenient way to support long-term hair health. By consistently using Mintop Solution, users can achieve a fuller appearance and restore their natural hair growth cycle.

Active substance: Minoxidil
SKU: Mintop Solution Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Mintop Solution belongs to a class of dermatological agents categorized as hair growth stimulants and topical vasodilators. Active minoxidil solution is available over-the-counter in the United States for the management of androgenetic alopecia in adult men and women.

The formulation is intended strictly for topical application directly onto affected areas of the scalp. Consistent daily administration according to clinical instructions is required to maintain observed hair growth effects and prevent regression of hair loss.

Attribute Product Details
Active ingredient (INN) Minoxidil
Therapeutic class Topical hair growth stimulant / Peripheral vasodilator
Dosage form Topical solution (2% or 5%)
Route of administration Topical (scalp application only)
Primary purpose Treatment of androgenetic alopecia (pattern baldness)
Prescription status Over-the-counter (OTC)
Storage conditions Controlled room temperature 68°F to 77°F (20°C to 25°C)

Clinical Profile and Mechanism

Pharmacological Characteristics

How the drug works

The active ingredient in Mintop Solution is minoxidil, a potassium channel opener that functions as a direct-acting peripheral vasodilator when applied locally. On a cellular level, minoxidil hyperpolarizes smooth muscle cell membranes around arterial blood vessels supplying the hair follicles. This hyperpolarization leads to local vascular relaxation and increased microvascular cutaneous blood flow. Enhanced microcirculation delivers oxygen, glucose, and essential systemic nutrients directly to hair roots. Consequently, miniaturized hair follicles transition from the dormant resting phase (telogen) into the active growth phase (anagen). Over prolonged therapy, the active compound prolongs the duration of the anagen phase and increases follicle size, converting fine vellus hair into thicker terminal hair strands.

Main uses

Mintop Solution is indicated primarily for the stabilization and treatment of hereditary hair loss, clinically referred to as androgenetic alopecia. In males, it is applied to address thinning hair localized at the vertex (crown) of the scalp. In females, it is indicated for diffuse hair thinning across the front scalp and crown regions. Non-hereditary causes of hair shedding–such as acute telogen effluvium resulting from physical trauma, thyroid dysfunctions, nutritional deficiencies, severe iron deficiency, or scarring alopecia–are not primary indications for topical minoxidil. Application of topical minoxidil solution to non-scalp regions, such as facial hair stimulation (beard growth), represents an off-label use that has not been established as safe or effective by FDA evaluation guidelines.

What happens in the body

Topical application of Mintop Solution yields minimal systemic absorption of active minoxidil through intact scalp skin. Pharmacokinetic studies show that an average of approximately 1.4% to 2% of the applied dose enters systemic circulation, though variations depend on individual epidermal thickness and cutaneous barrier integrity. Peak plasma concentrations of absorbed minoxidil typically occur approximately 6 hours following topical scalp application. The systemic clearance of absorbed minoxidil relies predominantly on renal excretion, with roughly 95% of the systemically absorbed portion excreted in urine within 4 days. Serum concentration drops quickly upon discontinuation of administration due to rapid hepatic metabolic breakdown of the absorbed parent drug.

Safety, Dosing, and Practical Guidance

Safety and Administration Considerations

Dosing schedule

The standardized dosing regimen for topical minoxidil solution requires the application of 1 mL of liquid twice daily, approximately 12 hours apart, to completely dry scalp regions displaying hair loss. The total daily applied volume should not exceed 2 mL, regardless of the size of the affected scalp region. Users apply the solution utilizing the provided calibrated dropper or metered spray applicator, spreading the liquid gently over the scalp surface with fingertips. Hands must be washed thoroughly with warm water and soap immediately after handling the solution. The applied liquid requires approximately 2 to 4 hours to dry fully; washing the hair or applying styling products should be avoided during this window.

What you may notice early on

Within the initial 2 to 6 weeks of starting regular application, patients frequently experience a temporary increase in hair shedding. This initial shedding period occurs because resting telogen hairs are actively displaced as revitalized hair follicles enter the anagen growth phase. This accelerated shedding is a temporary pharmacological response and does not indicate permanent follicle injury or treatment failure. Measurable reduction in hair loss and visible regrowth generally require uninterrupted daily administration for a minimum of 4 months. If no stabilization or improvement in hair density is observed after 4 to 6 months of continuous compliant use, medical reassessment by a dermatologist is recommended.

Adverse reactions

Local cutaneous side effects represent the primary adverse reactions associated with topically administered minoxidil solutions. Reported dermatological reactions include scalp erythema, localized itching (pruritus), scaling, dryness, and transient burning sensations. These localized reactions are frequently linked to formulation excipients, such as propylene glycol or ethanol. Accidental migration of the liquid to non-target dermal areas may induce hypertrichosis, leading to unwanted facial hair growth. Systemic side effects are rare due to low bioavailability, but heightened absorption through compromised skin may precipitate dizziness, sinus tachycardia, orthostatic hypotension, fluid retention, or peripheral edema.

Important precautions

Mintop Solution must not be applied to scalp surfaces that are red, inflamed, infected, sunburned, or broken, as loss of epidermal integrity significantly accelerates systemic drug absorption. Individuals with underlying cardiovascular conditions–including coronary artery disease, history of heart failure, or unstable cardiac arrhythmias–should seek medical guidance prior to initiating treatment. Pregnant women should avoid using topical minoxidil due to insufficient human safety data during gestation. Minoxidil excretion into human breast milk following topical administration is not fully defined; lactating women should consult a licensed healthcare professional before use. The safety profile of topical minoxidil has not been established in pediatric populations under 18 years of age.

Compatibility with other medicines

Concomitant application of Mintop Solution alongside other topical scalp medications should be avoided unless explicitly directed by a prescriber. Co-application with topical corticosteroids, retinoids (such as tretinoin), or occlusive petrolatum-based ointments increases epidermal penetration and elevates minoxidil systemic bioavailability, increasing the risk of systemic adverse events. Systemic drug interactions remain rare; however, concomitant administration with oral antihypertensive agents, particularly peripheral vasodilators such as guanethidine, may theoretically potentiate orthostatic hypotensive effects. Patients should report all ongoing dermatological treatments, prescription medicines, and over-the-counter topicals to their healthcare provider.

Storage and Daily Handling

Practical tips

To achieve consistent target exposure and minimize unintended exposure, precise application technique is essential. The solution must be deposited directly onto the scalp epithelium rather than onto the hair shafts, as transdermal absorption occurs strictly through cutaneous tissue. Individuals residing in warm, humid regions, such as coastal areas of Florida, should allow extended drying time before applying headwear to prevent moisture entrapment. Avoid using heated hairdryers to hasten evaporation, as warm airflow accelerates liquid evaporation prior to proper drug absorption into the dermis.

If you skip a dose

If a scheduled dose of Mintop Solution is missed, the user should skip the missed application and resume treatment at the next scheduled time. The user must not double the volume applied or apply liquid more frequently to compensate for skipped doses. Applying excessive amounts of minoxidil does not accelerate hair regrowth and increases the risk of local skin irritation and systemic absorption. Interruption of therapy for prolonged periods will result in the gradual loss of regrown hair, with scalp conditions reverting to pre-treatment baselines within 3 to 4 months following complete cessation.

Storage and expiration

Mintop Solution should be stored at controlled room temperature, ideally between 68°F and 77°F (20°C to 25°C), with brief excursions permitted between 59°F and 86°F (15°C to 30°C). The container must remain tightly closed, stored upright, and kept away from open flames or direct heat, as the vehicle contains flammable alcoholic solvents. Store the container safely out of reach of children and domestic pets. Discontinue use and discard any bottle beyond the expiration date printed on the packaging. Unused medication should be disposed of in compliance with local environmental standards rather than flushed down household drains.

Frequently Asked Questions

What should I do if the solution accidentally contacts my eyes or sensitive skin?

If Mintop Solution comes into accidental contact with sensitive surfaces such as the eyes, abraded skin, or mucous membranes, rinse the affected area immediately with large amounts of cool tap water. If ocular irritation, burning, or redness persists after thorough flushing, seek evaluation from a medical professional.

Is it safe to wash or color hair while using topical minoxidil solution?

Routine hair hygiene and chemical cosmetic hair treatments (such as dyeing or perming) can be continued during minoxidil use. However, the scalp should be washed thoroughly to remove all solution before chemical hair treatments are applied, and minoxidil should not be reapplied until scalp irritation from the chemical treatment has completely resolved.

How long must topical minoxidil be used to maintain newly grown hair?

Continuous daily application of minoxidil solution is required to preserve hair regrowth and maintain follicle revitalization. If application is permanently discontinued, the hair follicles return to their hereditary pattern of miniaturization, and newly regrown hair is typically shed within 3 to 4 months.

Can topical minoxidil be used simultaneously with oral hair supplements?

Combining topical minoxidil with non-prescription oral hair supplements (such as biotin or multivitamin formulations) generally presents no pharmacological incompatibility because systemic absorption of topical minoxidil remains minimal. Patients should consult their pharmacist to review all concurrent dietary supplements for potential overlaps.

What signs indicate that systemic absorption of minoxidil is occurring?

Systemic absorption of minoxidil may manifest as unexplained weight gain, peripheral swelling of the hands or feet, unexplained dizziness, lightheadedness when standing up, or a rapid, pounding heartbeat. If any of these systemic symptoms develop, discontinue application and contact a physician promptly.

In accordance with FDA guidelines.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

2%

,

5%

Package

1 bottles

,

2 bottles

,

3 bottles

,

4 bottles

,

6 bottles

Ενεργός Ουσία